Scarica l'app Stockscreener
0.1801
2.60%
-0.0048
Dopo l'orario di chiusura:
.18
-0.0001
-0.06%
Adaptimmune Therapeutics Plc Adr Borsa (ADAP) Ultime notizie
Pre-Market Titans: TTRX, BJDX & UPC Set The Pace - RTTNews
Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback? - ts2.tech
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real? - ts2.tech
Morning Market Movers: FEMY, PALI, COSM, Seeing Big Swings - RTTNews
Morning Market Movers: MRM, LEXX, WOLF See Big Swings - RTTNews
Stocks Moving Premarket: PEPG, WOK, ICU, And Other Gainers & Losers - RTTNews
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC - Yahoo Finance
Must-Watch Streaming Stocks Poised to Gain From Content Boom - Yahoo Finance
Is Hesai Group Sponsored ADR (HSAI) Outperforming Other Auto-Tires-Trucks Stocks This Year? - Yahoo Finance
Lenovo Finds 65% of IT Leaders Admit Their Defenses Can’t Withstand AI Cybercrime - Yahoo Finance
Why the Market Dipped But Li Auto Inc. Sponsored ADR (LI) Gained Today - Yahoo Finance
What Does Wall Street Think About Li Auto Inc. (LI)? - Yahoo Finance
Vestas Wind Systems AS ADR (VWDRY) Wind Turbines Orders on the Rise - Yahoo Finance
The Zacks Analyst Blog Highlights Walmart, Alibaba, Shell, Omega Flex and Weyco - Yahoo Finance
Investors Take Advantage Of 15.76% Gain In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - stocksregister.com
What Is Going On With Top KingWin Ltd (NASDAQ: WAI)? - stocksregister.com
Rio Tinto plc ADR Common Stock (RIO) Restructures to Focus on Profitable Assets - Yahoo Finance
Zacks.com featured highlights include Halozyme Therapeutics, Phibro, Leidos and PDD Holdings - Yahoo Finance
Adaptimmune Therapeutics CFO Wood sells $950 in shares - Investing.com
Nio Inc. ADR (NIO) Upgraded to ‘Overweight’ at JPMorgan on Strong Vehicle Demand - Yahoo Finance
Earnings call transcript: Adaptimmune Q2 2025 shows revenue beat, stock dips - Investing.com
Questex’s Fierce Pharma Week Announces Star-Studded Lineup with Jamie-Lynn Sigler, James Van Der Beek, Selma Blair, Kelly Killoran Bensimon and John Duffield to Provide Powerful Stories of Resilience and Healing - GlobeNewswire Inc.
Adaptimmune director Behbahani sells shares worth $229,171 - Investing.com
Are Investors Undervaluing ENGIESponsored ADR (ENGIY) Right Now? - Yahoo Finance
Adaptimmune Faces Nasdaq Delisting Notice Amid Compliance Issues - MSN
Adaptimmune Sales Jump 59 Percent - sharewise.com
Is Piedmont Lithium Inc.Sponsored ADR (PLL) Stock Outpacing Its Basic Materials Peers This Year? - Yahoo Finance
ADAP’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - Yahoo Finance
Wall Street Today: Dow, Nasdaq, S&P 500 open higher as investors focus on optimism over potential US Fed rate cut - Mint
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Ecor1 capital sells Adaptimmune Therapeutics (ADAP) shares for $6.89m - Investing.com India
Adaptimmune stock rating downgraded by H.C. Wainwright after asset sale - Investing.com South Africa
Adaptimmune Therapeutics stock plunges after selling cell therapy assets By Investing.com - Investing.com India
Adaptimmune Therapeutics stock plunges after selling cell therapy assets - Investing.com
Adaptimmune sells cell therapy assets to US WorldMeds for $55 million - Investing.com
XPeng Inc. Sponsored ADR (XPEV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect - Yahoo Finance
Mizuho downgrades Adaptimmune stock on solvency concerns - Investing.com
Financial Metrics Unveiled: MARA Holdings Inc (MARA)’s Key Ratios in the Spotlight - DWinneX
Best Momentum Stocks to Buy for June 12th - Yahoo Finance
Context Therapeutics names new CMO to advance T cell therapies By Investing.com - Investing.com South Africa
Context Therapeutics names new CMO to advance T cell therapies - Investing.com
KANZHUN LIMITED Sponsored ADR (BZ) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Adaptimmune Therapeutics earnings beat by $0.09, revenue fell short of estimates - Investing.com UK
Healthy Upside Potential: Merus N.V (MRUS) - Sete News
How should investors view Jianzhi Education Technology Group Co Ltd ADR (JZ)? - uspostnews.com
CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105 - Yahoo Finance
All Markets & Instruments Available to Trade - Capital.com
Adaptimmune Therapeutics Plc ADR’s (ADAP) Stock Is Harder To Predict Than You Think - Stocksregister
Take off with Adaptimmune Therapeutics Plc ADR (ADAP): Get ready for trading - Sete News
ADAP (Adaptimmune Therapeutics Plc ADR) may reap gains as insiders became active recently - knoxdaily.com
AUTL’s Market Whiplash: -44.26% YTD Decline, -21.08% Plunge in 30 Days - investchronicle.com
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: Navigating Drops and Gains - investchronicle.com
ADAP underperforms with a -5.05 decrease in share price - uspostnews.com
Closing Figures: Myriad Genetics, Inc (MYGN)’s Negative Finish at 7.20, Down -4.00 - DWinneX
Stock Performance Spotlight: Adaptimmune Therapeutics Plc ADR (ADAP) Ends the Day at 0.26, Down by -5.05 - DWinneX
Let’s Jump Into The Geron Corp (NASDAQ: GERN) Stock Forecast - Marketing Sentinel
Bausch + Lomb Corp (NYSE:BLCO)’s 12-Month Price Target Is Now Set At 23. - Marketing Sentinel
B. Riley Financial Inc (NASDAQ:RILY) Shares Dropped -2.22% In A Week. Can It Continue Rising? - Marketing Sentinel
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) Could Really Rise To 4 In 12 Months, According To Analysts. - Marketing Sentinel
Is Live Oak Bancshares Inc (NYSE:LOB) A Better Buy Than Others After A -32.27% Fall In This Year? - Marketing Sentinel
Eventbrite Inc (NYSE:EB) Declines -81.18% In 2025; Are Investors Attracted By Its $2.10 Price? - Marketing Sentinel
The Adaptimmune Therapeutics Plc ADR (ADAP) had a good session last reading, didn’t it? - uspostnews.com
How should investors view Lazard Inc (LAZ)? - uspostnews.com
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):